Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.
Journal of Allergy and Clinical Immunology（2018）
摘要
Dupilumab 300 mg q2w significantly improved AR-associated nasal symptoms in patients with uncontrolled persistent asthma and comorbid PAR.
更多查看译文
关键词
Asthma,allergic rhinitis,perennial allergic rhinitis,comorbidity,dupilumab,nasal symptoms
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要